Can gliotoxin impair immune and endothelial function without proving neurologic disease?

Gliotoxin, a fungal secondary metabolite, has substantial experimental bioactivity, but the clinical meaning of a urinary result is fundamentally different from demonstrating toxin-mediated neurologic disease.

Experimental and mechanistic evidence

• Immune effects are well supported experimentally. Gliotoxin inhibits macrophage Fcγ-receptor-mediated phagocytosis at approximately 0.19–3.06 µM and can rapidly suppress neutrophil phagocytosis at nanomolar concentrations. It reduces TNF-α secretion, alters monocyte cytokine responses, and inhibits lymphocyte proliferation, with substantial effects reported at 25–200 ng/mL.
• A specific mechanism is inhibition of stimulus-induced NF-κB activation in T and B cells through impaired IκBα degradation. Actin remodeling/collapse contributes to impaired phagocytosis; with higher or prolonged exposure, apoptosis occurs in macrophages, dendritic cells, and CD8-positive T cells.
• Endothelial barrier disruption is directly demonstrated in vitro. In human iPSC-derived brain microvascular endothelial monolayers, gliotoxin at ≥1 µM for 2 or 24 hours reduced transendothelial electrical resistance and increased fluorescein permeability. Redistribution of F-actin and altered cell–matrix interactions provide a plausible cytoskeletal basis for leakiness. Mouse findings of increased blood–spinal-cord barrier permeability with CNS inflammation and demyelination are supportive.
• Experimental neurotoxicity, including neurite degeneration in human SH-SY5Y cells, makes neurologic effects biologically plausible but is not evidence of clinical causation.

Clinical interpretation of urine testing

• LC–MS/MS can analytically detect gliotoxin in urine, but no FDA-approved clinical test, validated reference range, disease-predictive threshold, or demonstrated relationship to exposure source, tissue burden, cerebrospinal-fluid concentration, or neurologic outcomes exists. Dietary exposure can also yield detectable mycotoxins.

Bottom line

• Gliotoxin can impair immune and endothelial function in experimental models, but an elevated urinary measurement alone cannot establish gliotoxin as the cause of neurologic disease; standard neurologic assessment and alternative diagnoses remain essential.